Latham & Watkins advises Ardian in its acquisition of a minority stake in Inovie

Inovie, the leading independent medical diagnostic provider in France, and Ardian, a world-leading private investment house, announce that they have entered into exclusive negotiations for the acquisition of a minority stake by Ardian in Labosud, Inovie group’s lead company. The entry was approved by a very large majority of the group’s shareholding biologists, who will reinvest significant capital as part of the transaction. The transaction remains subject to the consultation processes of the relevant Labosud employee representative bodies in accordance with applicable law. 

As part of the partnership with Ardian, Inovie will maintain independence and further develop its renowned model. The management team will remain in charge of business operations, and the biologists will retain a majority stake in Labosud’s as well as and voting rights, whilst continuing to be the cornerstone of Inovie’s operating excellence. 

Ardian’s investment aims to make Inovie a leader in an increasingly competitive market, and one of the best-positioned companies to face current and future public health challenges. With Ardian as a shareholder, Inovie will be able to pursue an ambitious external growth and diversification strategy based on the development of its specialties, an acceleration of its digital strategy, and international expansion. 

Latham advises Ardian with a corporate Paris team led by partner Gaëtan Gianasso with Michael Colle and Nicolas Alfonsi. Partner Xavier Farde with counsel Carla-Sophie Imperadeiro and Virginie Terzic advise on financing aspects. Partner Xavier Renard with Cécile Mariotti and Thomas Claudel advise on tax aspects, counsel Mathilde Saltiel advises on antitrust aspects and partner Matthias Rubner advises on employment aspects of the transaction.